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Abstract
This paper analyzes an emerging form of post-pharmaceutical health and its 
underlying regime of value in the global bioeconomy of regenerative stem cell-based 
medicine (RSCM). Animated by a vision to overcome drug-based therapies and 
their underlying political economies, RSCM pursues a form of regenerative health 
that is strikingly at odds with pharmaceutical regimes of drug research, regulation 
and therapy. To offer a theoretical account of these competing forms of health, the 
paper provides an analysis of the regimes of values that underpin pharmaceutical and 
regenerative health respectively. This analysis is done alongside three dimensions: 
the interlinkage between knowledge, technology and economic value creation; 
its relation to normative values and ethics; and conceptions and valuations of the 
biomedical subject and his/her body in biomedical research, intervention and 
innovation. Contrasting these two diverging regimes of health and value suggests 
that in RSCM the pharmaceutical logic of accumulating “surplus health” is not 
entirely dismissed but re-articulated in a regime based on the (re-)generation of 
regenerative biovalue through the extraction and ex vivo accumulation of “surplus 
vitality”. Finally, the article discusses “post-pharmaceutical health” as a sensitizing 
concept that offers new research avenues into emergent forms of health, value, 
and subjectivity beyond RSCM.
Keywords: Bioeconomy, Biovalue, Health regimes, Pharmaceuticals, Regenerative 
stem cell medicine, Regulatory pharmaceuticalization.
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Valores incorporados: salud post-farmacéutica y la acumulación 
de vitalidad excedente en la medicina de células madre 
regenerativas
Resumen 
Este artículo analiza una forma emergente de salud post-farmacéutica y su régimen 
subyacente de valor en la bioeconomía global de la medicina regenerativa basada 
en células madre (MRCM). Animada por una visión de superación de las terapias 
basadas en medicamentos y sus economías políticas subyacentes, la MRCM persigue 
una forma de salud regenerativa que está marcadamente en desacuerdo con los 
regímenes farmacéuticos de investigación, regulación y terapia de medicamentos. 
Para ofrecer una explicación teórica de estas formas de salud en competencia, el 
artículo proporciona un análisis de los regímenes de valor que sustentan la salud 
farmacéutica y la regenerativa, respectivamente. Este análisis se hace según tres 
dimensiones: la interconexión entre el conocimiento, la tecnología y la creación de 
valor económico; su relación con los valores normativos y la ética; y las concepciones 
y valoraciones del sujeto biomédico y su cuerpo en la investigación, intervención e 
innovación biomédicas. El contraste de estos dos regímenes divergentes de salud y 
valor sugiere que en la MRCM la lógica farmacéutica de acumular “salud excedente” 
no se descarta completamente, sino que se rearticula en un régimen basado en la 
(re)generación de biovalor regenerativo a través de la extracción y la acumulación 
ex vivo de “vitalidad excedente”. Finalmente, el artículo analiza la “salud post-
farmacéutica” como un concepto instigador que ofrece nuevas vías de investigación 
en formas emergentes de salud, valor y subjetividad más allá de la MRCM.
Palabras clave: Bioeconomía, Biovalor, Regímenes de salud, Medicamentos, Medicina 
regenerativa de células madre, Farmacologización reguladora.
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Introduction 
Since the turn of the millennium, stem cell therapies have been central to an innovative biomedical paradigm, so-called “regenerative medicine” (Webster, 2013). This regenerative stem cell-based medicine (RSCM) 
promises a new approach to disease research and treatment, especially 
for currently incurable diseases and for those for which pharmacological 
approaches fail to deliver effective therapies. But beyond promises to expand 
the spectrum of treatable medical conditions per se, RSCM casts a vision of a 
revolutionary new type of medicine based on actual regeneration, that is, on 
healing, rather than on mere symptom treatment. This post-pharmaceutical 
vision is further tied to a whole range of innovation promises such as the 
creation of novel industries and markets, the overhaul of dilapidated health 
systems, the enhancement of national competitiveness in a global knowledge-
based economy – or even culminating in the idea to reduce the individual 
and social pressure of aging, nourishing on the mythological fantasy of 
finally being able to defeat death (Cooper, 2008; Gottweis et al., 2009). 
High hopes and expectations on the side of all involved – patients, 
investors and policy makers, as well as biomedical communities and biotech 
firms betting on the speculative clinical and commercial value of RSCM 
– have created a veritable pressure to perform and bring stem cell-based 
therapies to clinic and market as rapidly as possible (Morrison, 2012). In 
a veritable “rush to the clinic” (Wilson, 2009) that has taken shape on a 
global scale, various clinical and corporate actors have sought to realize the 
promise of RSCM and deliver actual stem cell-based therapies to patients 
in need (Salter et al., 2015; Rosemann et al., 2016; Bharadwaj, 2018). 
Yet, not only have expectable challenges to the clinical translation process 
curbed hopes for rapid clinical uptake (REFs); strikingly divergent visions of 
what desirable and responsible innovation pathways for regenerative stem 
cell-based therapies are in the first place have also sparked substantive 
conflicts within and beyond biomedical communities (Haddad et al., 2013; 
Rosemann; Chaisinthrop, 2016). 
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Whereas large parts of Western biomedical communities promote 
innovation pathways that follow, by and large, the “pharmaceutical pipeline” 
model of research, development and commercialization (ISSCR, 2018a), 
others have explored entirely different medical innovation approaches for 
stem cell-based therapies (Bharadwaj, 2014). All over the world, a plethora 
of stem cell therapy centers have emerged that offer treatments considered 
experimental – both in terms of their unproven developmental character as 
therapies and in terms of the tinkering with broader sociotechnical, legal and 
commercial models of biomedical innovation. Alarmed by the surge of these 
experimental practices, regulators and professional societies have sought 
to control the unregulated treatment market, often by trying to discipline 
“rogue” clinics and to re-inscribe experimental stem cell-based therapies 
into the regulatory regimes of pharmaceutical research and development. 
However, the numerous attempts to suppress both the supply and the 
demand for experimental stem cell treatments have remained largely 
unsuccessful globally (Sipp et al., 2017).
Against this background of the spread of these unruly practices, diverse 
forms of active resistance against this “regulatory pharmaceuticalization” 
(cf. Faulkner, 2012) of RSCM have taken shape. Whereas many stem cell 
therapy companies have just tried to dodge the regulatory actions through 
diverse tactics, other clinics and companies have taken up the battle to 
defend, in public debates or court trials, their vision of innovation in RSCM 
against what is seen as the stifling incorporation of stem cells into the 
pharmaceutical-regulatory complex (Tersal, 2012). 
In other instances, patients have spoken up publicly, signed petitions 
and protested in the streets in order to halt what is denounced as a 
“pharmaceutical seizure” of bodies and cells (Abbott, 2013; PR Newswire, 
2013). Soon, a range of powerful think tanks, academics and politicians (all 
perhaps for their own reasons) have started to support the cause and have 
criticized the apparent reluctance of established biomedical and regulatory 
institutions to adequately respond to changing needs and challenges 
pertaining to emerging innovative technologies. Moreover, proponents of 
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such “alternative” approaches to stem cell development started to organize 
and establish professional networks and institutions in an effort to normalize 
non-pharmaceutical innovation models in RSCM (Rosemann; Chaisinthrop, 
2016). As a result, past years have seen the emergence of some parallel 
universe of alternative institutions that develop and propagate competing 
standards for quality control, ethical assessments, and systems of accreditation 
for regenerative stem cell-based medicine (Blasimme, 2013, Rosemann; 
Chaisinthrop, 2016).
Towards a post-pharmaceutical form of health?
The initial proposition of this contribution is that what appears from 
the vantage point of Western biomedicine as “deviant” practices or crude 
anti-pharmaceutical sentiments within misguided or ignorant parts of 
RSCM communities does not simply represent some sort of teething 
problem of a nascent field of biomedicine. Rather, conceptualizing these 
seemingly “anti-pharmaceutical” contestations in terms of articulations 
of an emerging post-pharmaceutical regime of health helps us to discern 
broader problematizations of health, value and subjectivity at the onset of 
the 21st century.  
From this conceptual perspective, RSCM is a salient site of biopolitical 
articulation and experimentation for an emerging global bioeconomy of 
the life sciences, in which the nexus between health and biomedicine is 
being reimagined and reconfigured. The central thesis of this article is that in 
RSCM not only innovative products and possibly better therapies are being 
developed, but that also the meaning of health itself is at stake – that is, how 
health is conceptualized and rendered intelligible as an object of knowledge, 
how it ought to be produced, promoted, valued, commodified, delivered, 
and consumed as a good, and who the subjects are in these processes. 
On these grounds, this article offers a theoretical account of emerging 
post-pharmaceutical health regimes by analyzing the nexus between health 
and value in RSCM and contrasting it with that of pharmaceutical regimes. 
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While the research that supports my argument is based on empirical case 
study research, which formed a part of my Ph.D. project (Haddad, 2016), 
the thrust of this article is essentially theoretical. Its focus is on how health 
and value co-constitute mutually in RSCM, and how this regime differs from 
the pharmaceutical regime of health and value it professes to supersede. 
To do so, I compare and contrast the two respective health regimes – 
pharmaceutical and regenerative – in an ideal-typical manner.   
The article proceeds as follows: In the next section, I draw on two case 
vignettes to illustrate and better contextualize the political contestations 
over the regulatory pharmaceuticalization of RSCM. Yet, the scope of the 
problem runs deeper than these political-phenomenological explorations 
of anti-pharmaceutical articulations might suggest and concern the very 
network of relationships between power, knowledge, subjectivity, and 
value that constitute and underpin health regimes. Therefore, the third 
section develops the theoretical framework and key concepts that guide 
the analysis of health regimes: health, value, knowledge, and subjectivity. 
Based upon these elaborations, the main analytical part of this paper 
carries out a theoretical and comparative analysis of pharmaceutical and 
regenerative health. Put in contrast, it is possible to discern substantive 
differences in the ways health and value are generated and accumulated 
in pharmaceutical and regenerative medicine. Whereas pharmaceutical 
regimes depend on the incessant growth of “surplus health” through the 
expansion of drug intake on an individual and population level, regenerative 
medicine strives to growth “surplus vitality” by maximizing the extraction 
and ex vivo preservation of somatic stem cells.
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Contesting the regulatory pharmaceuticalization of stem 
cell therapies
The clinical and commercial practices of experimental RSCM are at 
least as diverse as the forms of problematization, contestation, and resistance 
to regulation that have taken shape globally. While it is thus impossible 
to present any “exemplary” case, the small vignettes presented next are 
indicative for a particular type of political articulation that problematizes 
the relationships between patients, their bodies, and their own bodily stem 
cells in an expressively anti-pharmaceutical discourse.
Anti-pharmaceutical articulations
Around 2008, a private Colorado-based orthopedic clinic developed 
an innovative treatment based on the patient’s own bodily stem cells and 
started to market its treatment to patients (Cyranoski, 2012). The thrust of 
the clinic’s promissory vision was not only to provide effective treatments 
for chronic knee and back pain, but also to revolutionize orthopedics 
altogether by advancing less invasive regenerative approaches “beyond pills 
and scalpels”.  These practices, however, led to a conflict with the US Food 
and Drug Administration (FDA). The FDA reasoned that such bodily stem 
cell therapies are analogous to drugs and should be regulated accordingly. 
For this reason, the clinic’s activities arguably corresponded to a process of 
manufacturing and marketing of drugs for which it had neither the required 
marketing authorization nor the approval for clinical trials.
The clinic, in turn, argued that its approach was not about product 
development, but consists in an innovative procedure, which has greater 
similarities with genuinely medical practice fields – such as blood donation, 
artificial insemination, or organ transplantation – than with industrial drug 
production. Accordingly, the application of patient-own stem cell therapies 
falls within medical authority, which is explicitly protected from access 
by drug regulatory agencies. FDA’s competence, which is democratically 
legitimized by the US Congress, is indeed limited to control, in the name of 
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public health and consumer protection, the quality and safety of consumer 
goods sold in the pharmaceutical marketplace, but not the way medicines 
are prescribed and used by medical professionals in the clinic (Berry, 1997).
As the controversy worsened, the clinic carried the dispute to court. Its 
medical director responded and stressed militantly that the trial will settle 
the dispute once and for all:
[The] courts will decide if the FDA has regulatory authority over the adult stem 
cells that live in everyone’s body [...] [and whether] the government has the 
right to restrict a patient and their doctor from using a person’s own stem cells 
to treat disease. [We] believe that stem cells are body parts and not the property 
of the government or big pharma (PR Newswire, 2010, emphasis added).
Large parts of the media have picked up this David vs. Goliath narrative, 
stylizing the litigation as a showdown between the mighty drug regulator and 
a small clinic, which will set the future course and direction for regenerative 
medicine.
In this context, the advocacy group Patients for Stem Cells launched 
an online petition to support the cause, titled “Stop FDA shutting down 
adult stem cell research” (Tersal, 2012). Under the slogan of “My Body 
≠ Drug!”, the petition read as a manifesto against the pharmaceutical-
regulatory complex. Criticism was directed primarily against the FDA, 
which was framed as an aggressive agency that arguably had expanded 
its competence to the area of medical practice by trying to inscribe stem 
cell therapies into the legal framework for pharmaceutical research and its 
political economy of regulated drug markets. By using this argumentation, 
in turn, the agency could extend its authority not only to a new substance 
class, but rather to the entire field of medical practice: 
This classification of a person’s stem cells as a “drug” means the government 
is not only interfering in scientifically proven medical care but also they claim 
to have jurisdiction over your own body’s cells. This has wide implications 
of control of medicine and the loss of the individual’s rights to choose the 
medicine of their own preference. The extraction and re-injection of adult 
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stem cells is not medically different from an in vitro fertilization conducted 
outside the body (Tersal, 2012).
A similar controversy occurred in Italy over Stamina Foundation, a 
provider of experimental therapies particularly for pediatric conditions (Abott, 
2013). When authorities wanted to stop the experimental treatments due to 
pressure from concerned health professionals, there were massive protests. 
Patients and their families demanded a “right to treatment” and medical 
self-determination in the context of serious illness. “Il corpore è mio! – It 
is my body!” was the tenor of the protests against an allegedly illegitimate 
state intervention in the privacy of the body, personal autonomy, and the 
doctor-patient relationship. Simultaneously, images of children’s coffins 
taken through many major Italian cities, of women who staged their naked 
bodies in the activist protest style of the women’s rights organization Femen, 
as well as of people in wheelchairs who were angry about medical-state 
paternalism, were broadcasted by various media channels worldwide. In the 
wake of the protests, Italian courts temporarily lifted the regulatory action 
against Stamina and ordered a large, publicly funded study to be conducted 
to verify the efficacy – and thus legitimacy – of these treatment offers. 
Beyond drug access activism and anti-pharmaceutical sentiments
If mirrored against the experiences of (mostly Western) patients’ activism 
and “right to access” movements (see e.g. Epstein, 1996), these confrontations 
over bodies, rights, and medicines might appear familiar. However, we 
also find crucial differences that reach beyond the pharmaceutical form 
of struggles over drug research, regulation, and access. 
To begin with, there is the trade-off between innovation and regulation. 
Time and again, deregulation advocates have criticized that the institutions 
that intend to protect the health and safety of patients are in fact doing 
them harm through too much regulation. While the criticism voiced in the 
cases discussed here somewhat seems to reiterate this line of reasoning, it 
actually runs much deeper. Far from lamenting a state of excessive regulation, 
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the very authority of drug regulatory agencies as such is challenged as both 
politically illegitimate and scientifically inappropriate for RSCM innovation. 
Secondly, this challenge to drug regulatory regimes further resembles 
the many instances where patients were fighting for access to experimental 
treatments. From the 1980s onwards, participation in clinical trials was 
redefined as a social good that was vociferously demanded, for example by 
HIV/AIDS patients in the face of terminal, life-threatening illness (Epstein, 
1996). More recently, cancer patient groups have even gone a step farther 
and have demanded a constitutional right to obtain investigational drugs 
that are in mid and late stage clinical development, even if there is only the 
smallest chance that the drugs might benefit terminal patients (Annas, 2007). 
And yet, the contestations over RSCM fundamentally go beyond this logic of 
exception. First and foremost, as in the case of the Colorado-based clinic, 
the medical conditions where stem cell therapies are deemed desirable 
treatments do not have to be considered terminal. The promissory vision of 
a regenerative medicine, as discussed at the very beginning of this article, 
shifts the normative grounds for exceptional experimental interventions 
from matters of life and death to the realm of vitality of disease (Wahlberg, 
2014), that is to say, concerns for improved living conditions for the diseased 
and a better quality of life. 
Third, and closely connected, there is the phenomenon that patients form 
(sometimes labeled “unholy”) alliances with pharmaceutical corporations in 
their fight against the state’s stifling regulations. A small, yet consequential 
difference here is how the relationships between drug producers, patients-
consumers, and the state are imagined: in most alliances between patients 
and Pharma, the state is imagined to wrongfully insert itself between active 
producers (drug companies) and consumers (patients) of pharmaceutical 
technology. This argumentation operates based on a distinction, conceptual 
and normative, between production and consumption which is crucial for 
problematizations of ownership and access rights. By contrast, in those cases 
of RSCM that I outlined above, the state is allegedly playing another, more 
forceful role: in its attempt of regulatory pharmaceuticalization (Faulkner, 
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2012), the state is charged to expropriate the very bodily stem cells of 
patients, hence dispossessing them from their autogenous biocapital – the 
very means of production of regenerative therapies from their own bodily 
vitality. The flipside of this imagination is that of a harmonious doctor-patient 
dyad forcefully severed by state intervention.
Taken together, these observations indicate the very post-pharmaceutical 
horizon articulated in the promissory visions of RSCM. The stakes negotiated 
in RSCM can be grasped through what Charis Thompson (2018) describes 
as an aspiration for “better patients”, referring to both the “moral and 
epistemological work patients and their physicians and advocates do which 
makes the science better and thus makes their treatment work better”, 
and to “the sense of ‘being, feeling, or getting better’ that we apply to 
patients who are on the road to recovery or have reduced symptoms and/
or improved quality of life” (Thompson, 2018, p. viii-ix). 
Instead of being crude anti-pharmaceutical sentiments, these 
problematizations of bodies, rights, knowledge, authority, and value point 
to an incipient regime of health that is in large parts articulated against 
pharmaceutical notions of health and value. Before exploring these two 
competing health regimes further, however, we need to develop the 
conceptual framework first.
Conceptualizing health in the bioeconomy of regenerative 
medicine
Health/value
Health presents a high-ranking normative value in contemporary 
biopolitical societies – individually, socially, and politically. At the same 
time, in capitalist societies health is always already embedded in regimes of 
accumulation to produce value for capital (Sunder Rajan, 2017). If biomedical 
innovation strategies involve the coproduction of health as both a normative 
and economic value, a critical concept of health is needed for its analysis. 
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Health therefore is conceptualized as a regime, that is, a set of socio-technical 
relationships that include historically specific and sector-specific forms of 
knowledge, intervention techniques, and modes of subjectification. At 
stake analytically is the form of health, that is, its implicit logic, or practical 
“rationality”, constituted through its regime of value.1 Hence, a particular 
form of health cannot be analyzed independently from its particular regime 
that articulates – in its intertwined semiotic-material sense of “to spell out” 
and to “cobble together” – the institutional, epistemic, and normative logics 
and practices that allow health to be produced as a value. 
The effort to analyze the nexus between health and value calls for a 
perspective that considers “value” in different dimensions. To do so, this 
research draws on scholarship on pharmaceutical values by Joseph Dumit 
(2012b) and Kaushik Sunder Rajan (2017, p. 16-30), who, both in their 
distinctive ways, draw upon a Marxian critique of value. Following the 
approach delineated by Sunder Rajan (2017, p. 17ff), it is key to analyze 
value in at least three registers: in terms of surplus value for capital; in terms 
of norms and ethics; and in terms of an antinomy – a self-contradictory 
relationship between its inherent modalities, such as between use value 
and market value or between ethical values and capital value. It is this last 
quality that renders value a deeply political category, for this antinomy can 
never be fully resolved. Any value regime therefore must be understood 
as a contingent outcome of power struggles and negotiations that presents 
only a temporally stable and intrinsically fragile arrangement. 
It is through these lenses that I explore how health is articulated and 
produced (and contested) as a value in pharmaceutical and regenerative 
health regimes respectively. What is at stake, empirically and conceptually, 
then, are (1) the specific ways in which actual and projected use values of 
technology (pharmaceutical drugs and somatic stem cells respectively) and 
their actual or projected market values co-constitute in their corresponding 
forms of health (pharmaceutical and regenerative health respectively), and 
1 The concepts of “regime” and “rationality” draw on governmentality studies (see Dean, 
2010).
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(2) how the conflicting tensions between health as a capital value and as 
an normative value are aligned and stabilized in the respective regimes. 
These different theoretical concerns and entanglements I seek to capture 
with the notion of health/value.
Knowledge, value and the bioeconomies of the life science
Knowledge plays a central role in the bioeconomies of the life sciences, 
but assumes, as we shall see, different forms and functions in pharmaceutical 
and regenerative health respectively. Certainly, there is a politics to knowledge 
to the extent that there are struggles and contestations over which forms of 
knowledge count as valid in biomedical research and innovation processes. 
First and foremost, these struggles address tensions between different 
“levels” of evidence, e.g., between laboratory vs. clinical knowledge, or 
the role of large-scale clinical trials vs. case study research, but also whether 
and to which extent experiential/embodied “lay” knowledge form part of 
biomedical innovation and valuation practices. In the field of RSCM, these 
politics of knowledge often unfold alongside post-colonial legacies and a 
geopolitics of knowledge of good Western science vs. bad non-Western 
science (Bharadwaj, 2018). 
Central for a nuanced understanding of health is the relationship 
between knowledge generation and value generation. The nexus between 
knowledge and value in RSCM has frequently been discussed with reference 
to the “global bioeconomy”. Bioeconomy is best understood as a dominant 
policy narrative and a strategic vision of sociotechnical development based 
on the valorization of renewable biomaterials – from renewable energy 
sources to human body cells (Lettow, 2015). But the ideas and visions 
of what the bioeconomy is and how it can unfold and generate value 
remain largely indefinite and vary between countries and sectors. Hence, 
regenerative medicine is a central field of articulation and experimentation 
for the globally emerging bioeconomy (Cooper, 2008; Lettow, 2015), that 
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is, a field in which a specific vision of the bioeconomy is articulated and 
concretized.
Perspectives, however, that posit bioeconomy as “the new thing” and 
uncritically reproduce policy discourses of its revolutionary innovative 
character miss significant continuities that exist in the lineages of life, 
science and economy. With a return to Foucault’s work on biopolitics 
and authors such as Lars Thorup Larsen (2007), Melinda Cooper (2008), 
or Kaushik Sunder Rajan (2006), I approach the bioeconomy as a field of 
problematizations and practices in which life (biology) and value (economy) 
co-constitute mutually and in historically contingent ways. From this angle, 
both pharmaceutical and regenerative health regimes operate within a 
certain bioeconomy of the life sciences that need to be explored in their 
respective specificities. 
In this regard, Sabina Leonelli and Kaushik Sunder Rajan have coined the 
concept of knowledge/value, which they introduce in analogy to Foucault’s 
concept of knowledge/power (Sunder Rajan; Leonelli, 2013). Foucault 
developed the notion of knowledge/power in order to grasp how the 
intersecting regimes of knowledge (the human sciences) and forms of 
power (the disciplinary institution) are veritably coproduced – they cannot 
be understood in isolation of one another. Similarly, knowledge/value seeks 
to grasp the constitutive intersecting of knowledge generating practices 
and value generating practices in today’s knowledge-based economy. 
Whereas Foucault’s knowledge/power produces regimes of truth as its 
effect, knowledge/value produces mobile, convertible and translatable 
knowledge – knowledge that is valuable in different contexts, such as in 
the laboratory, the regulatory science office, the shareholder meeting, or 
the patient clinic. For this study, the notion of knowledge/value sensitizes 
the analysis to examine the specific coproduction of knowledge and value 
in the field of regenerative medicine in contrast to other articulations of 
knowledge/value, such as that at the heart of the pharmaceutical industry.
To make this specific to the field of RSCM, I moreover build on and 
develop Catherine Waldby’s (2002) notion of “biovalue”. In her early 
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work on stem cell research, Waldby conceives of biovalue as the “yield of 
vitality produced by the biotechnological reformulation of living processes” 
(Waldby, 2002, p. 310), that is, as the value-adding surplus of vitality. How 
this surplus is generated in the field of regenerative stem cell medicine and 
what specific form it takes needs to be discerned in its own terms. 
Finally, the sociotechnical relationships between life, knowledge, and 
value that underpin different forms of health also shape, and are shaped 
by, conceptions and valuations of the human body as well as the role of 
subjects of and in biomedicine. In addition to accounts on patient activism 
and political patienthood (Epstein, 1996), work on the ethopolitics, somatic 
selves and biological citizenship (Rose; Novas, 2005; Gibbon; Novas, 2008) 
provides important impulses. These literatures shed light on processes of 
subjectification and identity construction in relation to biomedical knowledge 
and technologies. However, these insights into the neoliberal technologies 
of individuals and of the self must be supplemented by work that focuses on 
the exploitation of subjects and their bodies in biomedical labor relationships 
– such as in the case of experimental subjects or tissue donors (Bharadwaj, 
2014; Cooper; Waldby, 2014). The practices that shape biological subjects 
and selves are therefore analyzed in relation to emerging forms of biocapital 
sensitive to the double processes of subjectivation and subjugation, a 
perspective aptly articulated by Sunder Rajan (2006):
On the one hand, what forms of alienation, expropriation, and divesture are 
necessary for a “culture of biotechnology innovation” to take root? On the 
other hand, how are individual and collective subjectivities and citizenships 
both shaped and conscripted by these technologies that concern “life itself”? 
(Sunder Rajan, 2006, p. 78).
On this basis, we are now prepared to analyze the idiosyncratic regimes 
of pharmaceutical and regenerative health respectively and contrast them 
through the prism of their bioeconomies of health, value, knowledge, and 
subjectivity that underpin them.
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The pharmaceutical form of health
The birth of pharmaceutical health is conditioned, historically and 
technologically, by the rise of the chemical and pharmaceutical industries 
since the late 19th century (Abraham, 2010). Since then, pharmaceuticals 
have become an integral part of contemporary societies and their material 
culture (Kleinmann; Petryna, 2006). After having contributed significantly to 
improving public health worldwide, the pharmaceutical industry committed 
to promote and enhance health. It presents itself as a research-based industry 
that focuses on the well-being of patients and public health. At the same 
time, however, pharmaceutical companies are committed to the capitalist 
growth and accumulation imperatives, so they must generate profit and grow 
steadily, which means first and foremost to sell as many drugs as possible. 
Here, we are confronted with an antinomy of pharmaceutical values: how 
is it possible that the pharmaceutical enterprise advances technologically 
and in its mission (making people healthier), and at the same time is able 
to perpetuate and expand its economic growth model (selling more drugs)? 
One tentative answer is that Pharma produces health in a special form: as 
a pill that, if taken regularly, mitigates symptoms. Hence, the preferential 
commercial interest is in a form of therapy that has a positive effect on 
the health level of the largest possible population, but only as long as 
they consume their medication regularly and over a prolonged period – 
“Drugs for Life”, as Joseph Dumit (2012a) accurately captures this business 
model. The motto of a transnational pharmaceutical company involuntarily 
sums up this logic: “We care for healthier patients” – healthier, yes, but 
patients, nevertheless. Because when a drug actually heals a disease, the 
pharmaceutical industry loses a source of profit.
Critics therefore often polemicize that the pharmaceutical industry 
is only interested in increasing their profits – quite in contrast to their 
rhetorical call to “enhance health” – and underpin this claim with reference 
to countless drug scandals, relentless speculation with drug prices, or cases 
of instrumentalization and exploitation of subjects in clinical trials. In this 
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critique of pharmaceutical profit logic, the concept of health is a cynical 
and ideological one – the declared goal of health maximization is only 
maintained until it comes into conflict with profit maximization.
Growing health: surpassing barriers to medication
In order to gain a more complex understanding of pharmaceutical 
health, I will draw on the work of Joseph Dumit (2012a, 2012b) and explore 
the pharmaceutical value regime and its rationality. In an effort to move 
beyond the apparent antinomy between the growing capital value (the 
economic imperative) and growing health (the moral imperative), Dumit’s 
analysis is inspired by Marx’s and Foucault’s method of immanent critique. 
Dumit starts his critique by taking seriously the discourses and practices of 
the pharmaceutical industry – and its declared goal to, literally, grow health.
The main problem faced by the pharmaceutical industry is, then, what 
Dumit describes as the problem of “accumulation of drugs in the body”, 
which implies that the biological and normative barriers to medication are 
overcome in order to increase individual and collective drug intake.
An opportunity for this was created by the rise of an epistemology of risk 
factors, and, in particular, of molecular biological diagnostics. Through the 
transformation of clinical diagnostics based on genetics, which is commonly 
referred to as biomedicalization (Clarke et al., 2003), a new truth discourse 
of deficient health developed in which everyone is potentially at risk of 
illness (Lemke, 2011).
This new discourse, which redefined health and illness as a continuum 
of potentials, formed the epistemic basis for extending drug use from 
the clinical to the prophylactic phase – that is, from actual patients who 
subjectively feel a burden of suffering to potential or “becoming” patients. 
In other words, it is not just about improving the health of actual patients, 
but also about intervening in the pre-symptomatic phase in order to delay 
or prevent the possible onset of a disease. This extension of the treatment of 
diseases to disease potentials, which has also greatly expanded drug markets 
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from the clinic into society, has fundamentally changed the “medical gaze” 
since the birth of the clinic (Foucault, 1963) over the last century.
The problem that follows here, and that presents itself as simultaneously 
epistemological, normative, and economic, is that of boundary drawing: 
i.e., the definition of a threshold in the risk continuum, where the onset 
of prophylactic medication is justified, in order to delay the probable 
appearance of clinical symptoms or to alleviate the course of a disease.
The strategy of pharmaceutical marketing therefore consisted to a 
considerable extent in influencing treatment guidelines issued by, for example, 
medical associations or public health organizations. These define when and 
under what circumstances a particular drug is indicated in a diagnosis. These 
treatment guidelines are typically based on expert opinion and clinical 
trials findings, and are issued by the competent medical specialties. The 
pharmaceutical industry’s strategy is to redefine these thresholds in order 
to not only broaden the range of possible indications for existing drugs, but 
also to move forward the point in time when medication is indicated. In 
order to be able to translate this strategy into the rationality of health care 
systems – including payers and practitioners – this strategic interest has to 
be justified rationally and hence be articulated in the register of medical 
or health economic discourses. It is at this point that clinical trials assume 
a vital role in these politics of evidence-based norm-setting processes.
Clinical trials and the value of safety
Clinical trials are paramount in drug research and development 
(Marks, 1997). They serve different purposes in different contexts: Their 
primary function is to produce knowledge about the safety and efficacy 
of medicines, which is a prerequisite for regulatory approval from drug 
authorities. The pharmaceutical regime relies on a strict separation of research 
and treatment, which is rationalized in both a scientific and ethical way. 
Drug development depends scientifically on clinical research on human 
subjects, whose safety (as research subjects) is the overarching ethical and 
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regulatory concerns. The ethical debate about clinical trials is therefore 
always one of its implementation, which is subject to strict principles and 
requirements (Wahlberg; McGoey, 2007). Downstream, the drugs available 
on the market then need to be approved through scientific assessment 
once again, in order to make their consumption safe for users (patients).  
The biopolitics of pharmaceutical safety is thus characterized by a 
constitutive superimposition of the laboratory and the clinic: it is only 
when a drug has been tested on humans that it can be used for treatment 
of humans (Haddad, 2010). While this antinomy between research and 
treatment is probably characteristic of modern medicine as such, it was 
institutionalized in a specific way in the US and in Europe in the 1960s, 
and has become implemented globally from the 1990s onwards (Sunder 
Rajan, 2017). The ethics of these by now global regimes can be understood 
primarily as based on an ethics that predominantly values safety, which 
relies on the constitutive separation of production (clinic as laboratory) and 
consumption (clinic as market): the protection of subjects in clinical trials, 
on the one hand, and the protection of the population from dangerous or 
unchecked medicines, on the other. 
The biopolitical paradox of this safety precaution is that a drug becomes 
all the more “safe” for its use, the greater the number of experiments 
performed and the larger and more representative the experimental groups 
involved in it are (Haddad, 2010). Clearly, this normative distinction of 
research and care has become, time and again, blurred in practice, and was 
expressively criticized as unethical by patients with terminal illness, such as 
the HIV/AIDS movement in the 1980s (Epstein, 1996). Nonetheless, this 
separation remains a constitutive norm of pharmaceutical health regimes. 
Since this form of safety relies on large-scale and therefore costly clinical 
trials, this specific ethics of safety also plays a crucial economic role. On 
the one hand, lengthy development due to the multi-phase clinical trials 
process produces significant costs for Pharma. On the other hand, the high 
organizational and financial costs of this process also benefit large companies 
that have the necessary specialists and infrastructures to sponsor clinical trials. 
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The existing quasi-oligopoly of global Big Pharma is, at least partially, justified 
in the name of safety. At the same time, the value tensions between safety 
and profits have led to increased outsourcing of clinical trials to emerging 
markets in low-income countries (Petryna, 2009). International regimes 
and their efforts to implement globally universal standards of “good clinical 
practice” thus serve to protect both subjects and patients worldwide, and 
sustain the political economy of the Western pharmaceutical industry and 
its hegemonic value regimes (Sunder Rajan, 2017).
Clinical trials as knowledge/value generator
Clinical trials, however, play an important role also in the context of 
the pharmaceutical accumulation strategy of health and value, which is 
why Dumit (2012b, p. 64-9) describes them as the “machinery” of the 
pharmaceutical industry. Numerous studies have been commissioned to show 
that the modification of treatment guidelines is justified by underpinning the 
advantages of earlier treatment or a higher dose with scientific evidence. 
Contrary knowledge is not “suppressed” (albeit this happens, too), but 
simply not produced – and thus does not form part of the pharmaceutical 
knowledge system. In a context of contemporary societal division of labor, 
in which most of the clinical knowledge production is carried out by private 
capitalist corporations, this regime also produces systemic effects: The 
resulting selectivity of knowledge about indication, medication, dosage, etc. 
is further propelled by a strategic “will to ignorance” (McGoey, 2012), such 
as when a drug should be discontinued or its dose reduced. In this context, 
clinical trials not only serve the function of a sophisticated marketing tool, 
but also constitute the “machine” for the production of pharmaceutical 
knowledge/value, which is central to the understanding of health in the 
context of pharmaceutical biopolitics.
For Dumit, the quest for preventive health mediated through an 
epistemology of risk factors and clinical trials can be understood as the 
creation of surplus health as the central pharmaceutical rationality for growing 
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value. Paralleling Marx’s analysis of concrete and abstract labor in the creation 
of surplus value, surplus health presents an abstract category of Health (with 
capital H) that, while always the product of concrete human health, does 
not quite correspond to subjective feelings of embodied healthiness. The 
steady expansion of consumption and the steady suppression of natural 
and normative barriers to medication must therefore be understood as the 
production of “surplus health”, which forms the basis of pharmaceutical 
valorization (Dumit, 2012b).
Taken together, the contours of the pharmaceutical regime of health 
become evident, which persist not in the elimination of illness, but in the 
management of its symptoms that is preferably accomplished through 
prophylactic and chronic medication. It also relies on the qualitative and 
quantitative extension of medication, rationalized by knowledge produced 
by clinical trials and stabilized in treatment guidelines. The ethics of the 
pharmaceutical regime is an ethics of safety, based on an institutional 
separation between production and consumption of standardized products 
sold in regulated markets.
Post-pharmaceutical regenerative health
With pharmaceutical health as a contrast foil, I now want to examine 
the logics of regenerative health in stem cell medicine. If the guiding vision 
of stem cell medicine is regeneration – that is, actual healing – then the 
question arises which valorisation logic of knowledge and bodies underpins 
the logic of regenerative health, or: What is the accumulation of post-
pharmaceutical health/value based on?
Accumulating biovalue
For at least the last twenty years, RSCM has spawned a new truth 
discourse of health and disease that has shaken certain basic assumptions of 
conventional biomedicine. Human cell technologies have allowed human 
cells to be isolated and propagated in the laboratory. In conjuncture with 
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a variety of legal technologies that helped to disentangle human cells from 
the subjects’ body proper and render them independently “propriable” 
(Cooper; Waldby, 2014), these developments have paved the way to make 
living cells viable for circulation (Lettow, 2015). 
In the first years of adult stem cell therapies, RSCM mainly capitalized 
on experimental and ad-hoc treatments based on patients’ own body 
stem cells. In such procedures, patients are treated with their own cells 
extracted only shortly – typically only a few hours or days – before they 
are reinserted to the diseased location. The customers of RSCM offerings, 
hence, had been predominantly actual patients with a high level of suffering 
or life-threatening illnesses with no prospect of effective therapies from the 
established conventional medical spectrum. In recent years, however, the 
field has undergone significant changes. A different model geared towards 
a long-term valorization of stem cell therapies has gathered momentum 
that complements the model of immediate treatment offerings. In this 
emerging model, extraction and long-term storage of a patient’s stem cells 
is key both in clinical and commercial regard. Bio-banks were founded as 
sites where cells and tissue samples are stored under appropriate technical 
and regulatory conditions designed to maintain the quality, genetic stability, 
and biological potency of human cells ex vivo (Hauskeller; Beltrame, 2016). 
Consequently, no longer the clinical treatment center, but rather the bio-
bank became the institutional nodal point, assuming a crucial role for the 
long-term accumulation of value.
Clinically, there is the assumption that a greater quantity of stem 
cells is available from a young and healthy individual, compared to an 
older individual afflicted by disease, but also that the quality of the cells – 
understood in terms of their potency and regenerative capacities – is better. 
It follows from a biomedical point of view that it makes sense to remove 
stem cells as early as possible and store them, so that they can be used as 
a regenerative resource in the case of disease. 
This knowledge has direct bearing on bioeconomic value accumulation: 
The strategic-commercial goal here is to make as many people as possible 
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clients of stem cell banks and to manage the largest possible quantity of 
their stem cells for as long as possible – the extraction and extracorporeal 
storage of vitality. A process similar to that of the shift, in pharmaceutical 
logics, from actual disease to disease potentials can be observed here: the 
systematic expansion from actual to potential future patients. Individuals 
are interpellated simultaneously as potential patients, as proactive managers 
of their medical future, and as owners of their stem cells to store them (and 
those of their relatives, or, at company level, their employees) in stem cell 
banks, so they can resort to it in case of illness. Again, the epistemology of 
risk factors comes into play, but not to justify a pre-symptomatic treatment, 
but to rationalize the extraction of body stem cells as early as possible and 
in the largest possible quantities.
In this context, adult stem cell companies have begun to position 
themselves less as research-based companies or clinical treatment centers 
narrowly understood, but as biomedical service providers and “brokers” 
– intermediaries that not only organize clinics, clients, and their cells, but 
also mediate between biomedical present and future.
Generating speculative surplus vitality
If the pharmaceutical valorization of health consists in the production 
of abstract “surplus health” based on symptomatic therapy and increased 
medication, how can one understand the bioeconomy of regenerative 
health, whose post-pharmaceutical vision is founded on the promise of 
effective treatment and recovery?
So far we have seen that at its core is the collection and storage of 
stem cells as biocapital – a resource to re-generate vitality. Moreover, the 
following logic applies: The “younger” the body of which stem cells are 
extracted and the more of them are stored, the higher their potential use 
value. Here, we find a double speculative logic of biovalue – not only 
subjective and personal, but also technoscientific. On the one hand, this 
bioeconomy of RSCM articulates a logic of anticipatory self-care, as it 
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interpellates subjects as prudent managers of their vitality by preparing 
themselves for a possible emergency in the future. On the other hand, in 
view of the present state of the actual possibilities of RSCM, which stands in 
stark contrast to the enormous biomedical promise of RSCM in the future, 
one speculates on the latter: on great advances of treatment options in the 
future, which can then be translated into surplus vitality conserved in the 
form of one’s own stem cell bank. 
This collapsing boundary between production and consumption is also 
reflected in the register of ethical subjectification, as consumers of their own 
stem cells become (co)producers of biovalue. Against this background, the 
subject of regenerative health fashions itself as a rational subject of precaution 
and a subject of speculative investments in future biocapital. In doing so, 
clients not only invest in their individual biomedical future, but also in the 
technoscientific development of the field of regenerative medicine, the 
advancement of its clinical application, and of knowledge infrastructures. 
Through the lenses of Catherine Waldby’s (2002, p. 310) notion of 
biovalue as the value-adding surplus of vitality yielded by the “biotechnological 
reformulation of living processes”, we can now discern the form of biovalue 
encapsulated in the making of post-pharmaceutical health in RSCM. This 
regenerative biovalue is produced in the accumulation of “surplus vitality”, 
whereby its logic lies in the extraction, storage, and preservation of vitality 
in the context of a speculative bioeconomy of regenerative medicine. 
Somewhat akin to Dumit’s notion of “Health”, vitality here must not be 
understood as a concrete embodied state of well-being, strength, and 
healthiness experienced by a subject, but rather as a material abstraction 
in the form of extracted stem cells.
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Discussion: Towards an incipient future of post-
pharmaceutical health?
In RSCM an incipient form of regenerative health can be identified 
that significantly diverges from the dominant pharmaceutical regime in 
many respects. 
The health regimes of the 20th century, which were based in large 
parts not merely on pharmaceutical drug products, but also on specific 
pharmaceutical logics of producing and valuing health – economically, 
politically, ethically –, are problematized and challenged by the emergent 
regime of RSCM. Yet, far from simply being “anti-pharmaceutical”, it would be 
more precise to suggest that RSCM articulates a form of post-pharmaceutical 
health that does not entirely dismiss the logics of pharmaceutical regimes 
of health and value, but significantly reconfigures them. 
When compared and contrasted, pharmaceutical and regenerative 
health hence reveal crucial differences in the ways biomedical research, 
treatment, and innovation are articulated into regimes of value. First, 
in a growing domain of somatic stem cell therapy, the concept of drug 
development is being questioned in favor of an experimental medical 
innovation process, shifting the place of biomedical innovation from the 
bounded space of the pharmaceutical pipeline into a more diffuse field 
between clinic and market. At its present state of development, we find a 
rather diminished role for controlled clinical trials as principal technology 
for knowledge/value – knowledge that produces surplus for capital. Among 
other things, this is probably due to the fact that in efforts to accumulate 
surplus, regenerative health shifts the focus from pre-symptomatic medication 
(justified by evidence from clinical trials) to pre-onset extraction of stem 
cells. The fact that stem cell applications are commodified not so much 
as standardized “off-the-shelf” products (such as drugs), but rather as 
procedures – operations performed by clinicians –, in a global biomedical 
service economy that are dependent on a patient’s own bodily materials, 
gives shape to a different biopolitics of economic and ethical valuation 
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of vitality: sociotechnical practices of appropriation, expropriation, and 
valorization of bodies and of health and disease on the one hand; ethical 
valuations and rights to treatment, ownership, and access, on the other. 
How do these observations speak to our understandings of health in 
the emerging global bioeconomy? The assertion that bioeconomy does not 
only present new biotechnological markets but constitutes a new field of 
(re)productive forces in contemporary techno-scientific capitalism is key: 
the struggles fought over the proper regulatory frameworks address the 
entire web of hierarchically arranged values and power relations between 
biomedicine, industry, and the state, which are symbolically and materially 
inscribed into the bodies of patients. Hence, RSCM does not only go beyond 
Pharma by providing a different – and self-declaredly better – means of 
providing health in the sense of an advanced biomedical technology, 
but challenges and alters the very ways in which health and disease are 
conceptualized, valued, and acted upon, and how biomedical innovation 
processes are imagined and pursued.
What are, then, the broader empirical and political prospects of this 
emergent form of post-pharmaceutical health? To begin with, as a truly 
global phenomenon the spread of clinical and commercial forms of patient-
based stem cell therapies is rapidly growing, with no signs of stopping. 
Largely, this field is driven by experimental treatment applications that 
are difficult to regulate (Sipp et al., 2017). Thousands of patients who 
have the necessary purchase power to buy such expensive treatments 
on a global marketplace “just do it”, and can do it simply because of the 
sociotechnical relations that underpin the global bioeconomy of RSCM, 
such as the easy technological basis for autologous therapies, the regulatory 
discrepancies between different biomedical jurisdictions, social media 
propagation, cheap flights and huge health care asymmetries on a global 
scale, etc. The direct treatment approach is increasingly complemented by 
a growing industry of mostly private stem cell banks that provide broader 
sociotechnical and institutional infrastructures. Yet, at present, it is hard 
to anticipate whether and to what extent the pharmaceutical regime will 
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actually lose dominance. Current developments rather point to a trend of 
pluralization and superimposition of the two health regimes on a global 
scale (Rosemann; Chaisinthrop, 2016). Moreover, an increasing number of 
governments and public institutions are supporting precisely this emerging 
field of RSCM because of its huge innovation potential – often in open 
conflict with dominant biomedical communities, other state apparatuses, 
and biocapital factions (Haddad, 2016).
Finally, what, if at all, does the notion of post-pharmaceutical health help 
us to perceive and analyze beyond the realm of RSCM?  We have introduced 
post-pharmaceutical health as a sensitizing concept to explore to date 
dispersed developments that challenge the pharmaceutical rationality of drug 
research, commerce and treatment. These practical and politicized forms 
of critique target the global hegemony of vested interests of pharmaceutical 
corporations perpetuated by its particular regulatory frameworks, patent 
regimes, and innovation models. However, as the analysis of regenerative 
health makes clear, one should be circumspect of normative evaluations 
of post-pharmaceutical health, as they reproduce different yet similar 
accumulation logics through exploitation of subjects and expropriation of 
bodies. Future sociological research hence might examine emergent forms 
of post-pharmaceutical health in different fields and spaces, and map out 
and critically analyze the struggles, conflicts, and processes over, within 
and at the margins of pharmaceutical rationalities and their corresponding 
regimes of value.
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